| Literature DB >> 22260715 |
Silvia D'Arezzo1, Simone Lanini, Vincenzo Puro, Giuseppe Ippolito, Paolo Visca.
Abstract
BACKGROUND AND METHODS: Pseudomonas aeruginosa is a major infectious threat to immunocompromised patients. We recently reported a fatal epidemic of multidrug-resistant P. aeruginosa in an onchoematology unit, linked to massive contamination of a triclosan-based disinfectant. The aim of this study is to evaluate the antimicrobial activity of triclosan and chlorhexidine digluconate against the epidemic strain of P. aeruginosa, to confirm the hypothesis that the soap dispenser acted as a continuous source of the infection during the outbreak, and to explore the potential role of triclosan in increasing the level of resistance to selected antibiotics.Susceptibility tests and time-kill assays for disinfectans were performed using two commercial formulations containing triclosan and chlorhexidine digluconate, respectively. Antibiotic susceptibility testing was performed by the broth microdilution method.Entities:
Year: 2012 PMID: 22260715 PMCID: PMC3292827 DOI: 10.1186/1756-0500-5-43
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Figure 1Time-kill kinetics of .
Antibiotic susceptibility in unadapted and triclosan-adapted P.aeruginosa
| Antibiotic MIC (mg/L) b | ||||||
|---|---|---|---|---|---|---|
| TET | CIP | AMK | LVX | CAR | CHL | |
| Unadapted | 32 | 16 | 4 | 8 | 128 | 128 |
| Unadapted plus PAβN (50 μM) | 16 | 4 | 2 | 2 | 64 | 64 |
| Unadapted plus CCCP (100 μM) | 16 | 8 | 2 | 4 | 64 | 64 |
| Adapted a to 3,400 mg/L triclosan | 64 | 32 | 8 | 16 | 256 | 256 |
| Adapted a to 3,400 mg/L triclosan plus PAβN (50 μM) | 32 | 8 | 4 | 4 | 64 | 64 |
| Adapted a to 3,400 mg/L triclosan plus CCCP (100 μM) | 32 | 16 | 4 | 8 | 64 | 64 |
aAdaptation was achieved by serial subculturing in stepwise increasing triclosan concentrations up to 3,400 mg/L triclosan (see Methods). The experimental data were confirmed by three independent replicates
bBreakpoint criteria were as follows. TET: susceptible, ≤ 4 mg/L; intermediate, 8 mg/L; resistant, ≥ 16 mg/L; CIP: susceptible, ≤ 1 mg/L; intermediate, 2 mg/L; resistant, ≥ 4 mg/L; AMK: susceptible, ≤ 16 mg/L; resistant, ≥ 32 mg/L; LVX: susceptible, ≤ 2 mg/L; intermediate, 4 mg/L; resistant, ≥ 8 mg/L; CAR: susceptible, ≤ 128 mg/L; intermediate, 256 mg/L; resistant, ≥ 512 mg/L; CHL: susceptible, ≤ 8 mg/L; intermediate, 16 mg/L; resistant, ≥ 32 mg/L [12]
MIC minimal inhibitory concentration; PAβN RND pump inhibitor phenyl-arginine-β-naphthylamide; CCCP protonophore carbonyl cyanide m-chlorophenylhydrazone; TET tetracycline; CIP ciprofloxacin; AMK amikacin; LVX levofloxacin; CAR carbenicillin; CHL chloramphenicol